• 1
    World Heath Organization (WHO). Fact sheet #312, August 2011.
  • 2
    Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the US. Diabetes Care 2009; 32: 22252229.
  • 3
    American Diabetes Association. Complications of diabetes in the United States. 2009. Available from: Accessed 5 January 2012.
  • 4
    Chew EY, Ferris FL 3rd, Csaky KG, Murphy RP, Agrón E, Thompson DJ, Reed GF et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 2003; 110: 16831689.
  • 5
    The American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34 (Suppl 1): S11-S61.
  • 6
    Wald G. The receptors of human color vision. Science 1964; 145: 10071017.
  • 7
    Zisman F, Adams AJ. Spectral sensitivity of cone mechanisms in juvenile diabetics. Doc Ophthalmol Proc Ser 1982; 33: 127131.
  • 8
    Adams AJ. Chromatic and luminosity processing in retinal disease. Am J Optom Physiol Opt 1982; 59: 954960.
  • 9
    Heron G, Adams AJ, Husted R. Foveal and non-foveal measures of short wavelength sensitive pathways in glaucoma and ocular hypertension. Ophthalmic Physiol Opt 1987; 7: 403404.
  • 10
    Johnson CA, Adams AJ, Lewis RA. Automated perimetry of short-wavelength-sensitive mechanisms in glaucoma and ocular hypertension; preliminary findings. In: Heijl A, ed. Proceedings of the VIIIth International Perimetric Society Meeting. Amsterdam: Kugler & Ghedini Publications, 1989. p 3137.
  • 11
    Johnson CA, Adams AJ, Casson EJ, Brandt JD. Blue-on-yellow perimetry can predict the development of glaucomatous visual field loss. Arch Ophthalmol 1993; 111: 645650.
  • 12
    Sample PA, Johnson CA, Haegerstrom-Portnoy G, Adams AJ. Optimum parameters for short-wavelength automated perimetry. J Glaucoma 1996; 5: 375383.
  • 13
    Han Y, Adams AJ, Bearse Jr MA, Schneck ME. Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy. Arch Ophthalmol 2004; 122: 18091815.
  • 14
    Bresnick G. Diabetic retinopathy viewed as neurosensory disorder. Arch Ophthalmol 1986; 104: 989990.
  • 15
    Bresnick GH, Palta M. Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch Ophthalmol 1987; 105: 929933.
  • 16
    Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog Retin Eye Res 1998; 17: 5976.
  • 17
    Tzekov R, Arden GB. The electroretinogram in diabetic retinopathy. Surv Ophthalmol 1999; 44: 5360.
  • 18
    Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Nakamura M. New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol Ther 2000; 2: 601608.
  • 19
    Lieth E, Gardner TW, Barber AJ, Antonetti DA. Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol 2000; 28: 38.
  • 20
    Barber AJ, Lieth E, Khin SA, Anonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes: early onset and effect of insulin. J Clin Invest 1998; 102: 783791.
  • 21
    Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 283290.
  • 22
    Sutter EE, Tran D. The field topography of ERG components in man: I. The photopic luminance response. Vision Res 1992; 32: 433446.
  • 23
    Bearse MA Jr, Sutter EE. Imaging localized retinal dysfunction with the multifocal electroretinogram. J Opt Soc Am A Opt Image Sci Vis 1996; 13: 634640.
  • 24
    Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci 1999; 40: 26382651.
  • 25
    Hood DC, Holopigian K, Greenstein V, Seiple W, Li J, Sutter EE, Carr RE. Assessment of local retinal function in patients with retinitis pigmentosa using the multi-focal ERG technique. Vision Res 1998; 38: 163179.
  • 26
    Hood DC. Assessing retinal function with the multifocal technique. Prog Retin Eye Res 2000; 19: 607646.
  • 27
    Palmowski AM, Sutter EE, Bearse MA Jr, Fung W. Mapping of retinal function in diabetic retinopathy using the multifocal electroretinogram. Invest Ophthalmol Vis Sci 1997; 38: 25862596.
  • 28
    Lai YY, Chan W-M, Lai RYK, Ngai JWS, Li H, Lam DSC. The clinical applications of multifocal electroretinography: a systematic review. Surv Ophthalmol 2007; 52: 6196.
  • 29
    Hood DC, Frishman LJ, Saszik S, Viswanathan S. Retinal origins of the primate multifocal ERG: implications for the human response. Invest Ophthalmol Vis Sci 2002; 43: 16731685.
  • 30
    Hare WA, Ton H. Effects of APB, PDA and TTX on ERG responses recorded using both multifocal and conventional methods in monkey: effects of APB, PDA and TTX on monkey ERG responses. Doc Ophthalmol 2002; 105: 189222.
  • 31
    Han Y, Schneck ME, Bearse MA Jr, Barez S, Jacobsen CH, Jewell NP, Adams AJ. Formulation and evaluation of a predictive model to identify the sites of future diabetic retinopathy. Invest Ophthalmol Vis Sci 2004; 45: 41064112.
  • 32
    Bearse MA Jr, Adams AJ, Han Y, Schneck ME, Ng J, Bronson-Castain K, Barez S. A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog Retin Eye Res 2006; 25: 425448.
  • 33
    Ng JS, Bearse MA Jr, Schneck ME, Barez S, Adams AJ. Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest Ophthalmol Vis Sci 2008; 49: 16221628.
  • 34
    Harrison WW, Bearse MA Jr, Ng JS, Jewell NP, Barez S, Burger D, Schneck ME et al. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci 2011; 52: 772777.
  • 35
    Harrison WW, Bearse MA Jr, Schneck ME, Wolff BE, Jewell NP, Barez S, Mick AB et al. Prediction, by retinal location, of the onset of diabetic oedema in patients with non-proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2011; 52: 68256831.
  • 36
    Hood D, Li J. A technique for measuring individual multifocal ERG records. In: Yager D, ed. Non-invasive Assessment of the Visual System: Trends in Optics and Photonics. Washington, DC: Optical Society of America, 1997. p 3341.
  • 37
    Han Y, Bearse Jr MA, Schneck ME, Barez S, Jacobsen CH, Adams AJ. Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Visual Sci 2004; 45: 948954.
  • 38
    Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991; 98: 823833.
  • 39
    Hellstedt T, Immonen I. Disappearance and formation rates of microaneurysms in early diabetic retinopathy. Br J Ophthalmol 1996; 80: 135139.
  • 40
    Jewell NP. Statistics for Epidemology. Boca Raton, Florida: Chapmanand Hall, 2004.
  • 41
    Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44: 10491060.
  • 42
    Harrison WW, Bearse MA Jr, Ng J, Bronson-Castain K, Davila O, Schneck ME, Adams AJ. Clinically significant macular oedema cases are associated with multifocal electroretinogram abnormalities. Optom Vis Sci 2007; 84: E-abstract 075228.
  • 43
    Parks S, Keating D, Williamson TH, Evans AL, Elliot AT, Jay JL. Functional imaging of the retina using the multifocal electroretinograph: a control study. Br J Ophthalmol 1996; 80: 831834.
  • 44
    Parks S, Keating D, Evans AL, Williamson TH, Jay JL, Elliot AT. Comparison of repeatability of the multifocal electroretinogram and Humphrey perimeter. Doc Ophthalmol 1996; 92: 281289.
  • 45
    Harrison WW, Bearse MA Jr, Ng JS, Barez S, Schneck ME, Adams AJ. Reproducibility of the mfERG between instruments. Doc Ophthalmol 2009; 119: 6778.
  • 46
    Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248: 915930.
  • 47
    Tsilimbaris M. Intravitreal combination of triamcinolone acetonide and bevacizumab (Kenacort-Avastin) in diffuse diabetic macular oedema. Semin Ophthalmol 2009; 24: 225230.
  • 48
    Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB. Edwards AR, Ferris FL 3rd et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular oedema. Ophthalmology 2010; 117: 10641077.
  • 49
    Bronson-Castain KW, Bearse MA Jr, Neuville J, Jonasdottir S, King-Hooper B, Barez S, Schneck ME et al. Adolescents with type 2 diabetes: early indications of focal retinal neuropathy, retinal thinning, and venular dilation. Retina 2009; 29: 618626.
  • 50
    Bronson-Castain KW, Bearse MA Jr, Neuville J, Jonasdottir S, King-Hooper B, Barez S, Schneck ME et al. Early neural and vascular changes in the adolescent type 1 and type 2 diabetic retina. Retina 2012; 32: 92102.
  • 51
    Efron N. The Glenn A Fry award lecture 2010: ophthalmic markers of diabetic neuropathy. Optom Vis Sci 2011; 88: 661683.
  • 52
    Tam J, Dhamdhere KP, Manzanera S, Barez S, Bearse MA Jr, Roorda A. Disruption of the retinal parafoveal capillary network in type 2 diabetes prior to the onset of diabetic retinopathy. Invest Ophthalmol Vis Sci 2011; 52: 92579266.
  • 53
    Tam J, Dhamdhere KP, Tiruveedhula P, Lujan BT, Johnson RN, Bearse MA Jr, Adams AJ, Roorda A. Subclinical capillary changes in non-proliferative diabetic retinopathy. Optom Vis Sci. In press.